Revvity, Inc. (RVTY)
(Delayed Data from NYSE)
$121.25 USD
+1.86 (1.56%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $121.19 -0.06 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Net Sales: Life Sciences
- 1,292.34
- 1,292.91
- 897.72
- 596.59
- 1,746.16
- Revenue - Line of Business (LOBR)
- Net Sales: Diagnostics
- 1,459.06
- 2,019.73
- 2,931.94
- 2,066.94
- 1,137.51
- Income - Line of Business (LOBI)
- Adjusted operating income: Life Sciences
- 489.35
- 503.24
- 415.30
- 266.74
- 338.01
- Income - Line of Business (LOBI)
- Adjusted operating income: Diagnostics
- 320.93
- 781.99
- 1,432.77
- 1,010.36
- 315.96
- Income - Line of Business (LOBI)
- Adjusted operating income: Corporate
- -40.42
- -73.43
- -77.36
- -73.85
- -57.97
- Non Financial / Operating Metric (NFM)
- Organic revenue growth - Life Sciences
- 0.00
- 15.00
- 12.00
- -4.00
- 3.00
- Non Financial / Operating Metric (NFM)
- Organic revenue growth - Diagnostics
- -27.00
- -29.00
- 35.00
- 81.00
- 7.00
- Non Financial / Operating Metric (NFM)
- Organic revenue growth - Total
- -16.00
- -29.00
- 24.00
- 31.00
- 5.00